Marlous Langendoen-Gort

Marlous Langendoen-Gort

Auto-generated profile, based on publicly available information

Marlous Langendoen-Gort

Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice, De Boelelaan 1117, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2022 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
MLMarlous Langendoen-Gort
Marlous Langendoen-Gort
LGLenka Groeneveld
Lenka Groeneveld
CPCecilia A. C. Prinsen
Cecilia A. C. Prinsen
JBJoline W. Beulens
Joline W. Beulens
PEPetra J. M. Elders
Petra J. M. Elders
FRFemke Rutters
Femke Rutters
Patient-Reported Outcome Measures (PROMs) are important tools to assess outcomes relevant to patients, with Health-Related Quality Of Life (HRQOL) as an important construct to be measured. Many different HRQOL PROMs are used in the type 2 diabetes field, however a complete overview of these PROMs is currently lacking. We therefore aimed to systematically describe and classify the content of all PROMs that have specifically been developed or validated to measure (aspects of) HRQOL in people with type 2 diabetes. A literature search was performed in PubMed and EMBASE until 31 December 2021. Studies on the development or validation of a PROM measuring HRQOL, or aspects of HRQOL, in people with type 2 diabetes were included. Title and abstract and full-text screening were conducted by two independent researchers and data extraction was performed independently by one of the researchers. Data were extracted on language in which the PROM was developed, target population, construct(s) being measured, names of (sub)scales and number of items per (sub)scale. In addition, all PROMs and subscales were classified according to specific aspects of HRQOL based on the Wilson & Cleary model (symptom status, functional status, general health perceptions) to aid researchers in PROM selection. In total 220 studies were identified that developed or validated PROMs that measure (aspects of) HRQOL in people with type 2 diabetes. Of the 116 unique HRQOL PROMs, 91 (of the subscales) measured symptom status, 60 measured functional status and 26 measured general health perceptions. In addition, 16 of the PROMs (subscales) measured global quality of life. 61 of the 116 PROMs (subscales) also include characteristics of the individual (e.g. aspects of personality, coping) or environment (e.g. social or financial support) and patient-reported experience measures (PREMs, e.g. measure of a patient's perception of their personal experience of the healthcare they have received, e.g. treatment satisfaction), which are not part of the HRQOL construct. Only 9 of the 116 PROMs measure all aspects of HRQOL based on the Wilson & Cleary model. Finally, 8 of the 116 PROMs stating to measure HRQOL, measured no HRQOL construct. In conclusion, a large number of PROMs are available for people with type 2 diabetes, which intend to measure (aspects of) HRQOL. These PROMs measure a large variety of (sub)constructs, which are not all HRQOL constructs, with a small amount of PROMs not measuring HRQOL at all. There is a need for consensus on which aspects of HRQOL should be measured in people with type 2 diabetes and which PROMs to use in research and daily practice. PROSPERO: CRD42017071012. COMET database:http://www.comet-initiative.org/studies/details/956.

11 July 2022 in Current Diabetes Reports
Verified
Journal Article
Open access
PDF file
CTCaroline B. Terwee
Caroline B. Terwee
PEPetra J. M. Elders
Petra J. M. Elders
MLMarlous Langendoen-Gort
Marlous Langendoen-Gort
EEEllen B. M. Elsman
Ellen B. M. Elsman
CPCecilia A. C. Prinsen
Cecilia A. C. Prinsen
FRFemke Rutters
Femke Rutters
Purpose of review: We aimed to systematically evaluate the content validity of patient-reported outcome measures (PROMs) specifically developed to measure (aspects of) health-related quality of life (HRQOL) in people with type 2 diabetes. A systematic review was performed in PubMed and Embase of PROMs measuring perceived symptoms, physical function, mental function, social function/participation, and general health perceptions, and that were validated to at least some extent. Content validity (relevance, comprehensiveness, and comprehensibility) was evaluated using COSMIN methodology. Recent findings: We identified 54 (different versions of) PROMs, containing 150 subscales. We found evidence for sufficient content validity for only 41/150 (27%) (subscales of) PROMs. The quality of evidence was generally very low. We found 66 out of 150 (44%) (subscales of) PROMs with evidence for either insufficient relevance, insufficient comprehensiveness, or insufficient comprehensibility. For measuring diabetes-specific symptoms, physical function, mental function, social function/participation, and general health perceptions, we identified one to 11 (subscales of) PROMs with sufficient content validity, although quality of the evidence was generally low. For measuring depressive symptoms, no PROM with sufficient content validity was identified. Summary: For each aspect of HRQL, we found at least one PROM with sufficient content validity, except for depressive symptoms. The quality of the evidence was mostly very low.

2 September 2022 in Trials
Verified
Journal Article
Open access
PDF file
MLMarlous Langendoen-Gort
Marlous Langendoen-Gort
HAHiyam Al-Jabr
Hiyam Al-Jabr
JHJacqueline G. Hugtenburg
Jacqueline G. Hugtenburg
FRFemke Rutters
Femke Rutters
MWMaartje de Wit
Maartje de Wit
PEPetra J. M. Elders
Petra J. M. Elders
Background: Medication non-adherence is a prevalent health problem in people with type 2 diabetes mellitus (T2DM). Interventions have previously been developed to improve medication adherence, but inconsistent outcomes have been reported. A potential explanation for this inconsistency is a ‘one size fits all’ approach, with interventions not tailored to the needs and preferences of individuals. Therefore, the aim of this study is to evaluate the effectiveness of a personalised intervention programme aimed at improving adherence to oral antidiabetic and/or antihypertensive medication in people with T2DM. Methods: A parallel-group randomised controlled trial will be conducted in 40–50 community pharmacies in the Netherlands and the United Kingdom (UK). A total of 300 participants will be included and followed up for a period of 6 months. Participants will be people with T2DM identified as non-adherent to oral antidiabetic and/or antihypertensive medication, aged 35–75 years and mobile phone users. The intervention group will receive a personalised intervention programme that is based on one or more of the participants’ pre-defined non-adherence profile(s), namely (I) Knowledge and perceptions, (II) Practical problems, (III) Side effects and (IV) Negative mood and beliefs. The intervention comprises of one or more supporting modules, namely (I) Brief messaging, (II) Clinical medication review, (III) Medication schedule, (IV) Reminding messaging, (V) Medication dispensing systems, (VI) Smart messaging, (VII) Referral to general practitioner and (VIII) Unguided web-based Self Help Application for low mood. The control group will receive usual care including access to a publicly available informative diabetes website. The primary study outcome is medication adherence measured with a telephone pill count. Secondary outcomes are systolic blood pressure, HbA1c level, self-reported medication adherence, attitude and beliefs toward medication, satisfaction with diabetes treatment, health status and medical consumption and productivity cost. In addition, a process evaluation will be undertaken to establish the fidelity, reach and the extent to which intervention delivery is normalised in the daily practice of community pharmacy teams. Discussion: The study can lead to a personalised intervention programme that improves medication adherence in people with T2DM that are non-adherent to oral antidiabetic and/or antihypertensive medication. Trial registration: Dutch Trial Register, Trial NL8747, registered 02 July, 2020; ISRCTN Registry, ISRCTN36009809, registered 05 February, 2020.


17 November 2022 in Clinical Pharmacology in Drug Development
Verified
Journal Article
Open access
MLMarlous Langendoen‐Gort
Marlous Langendoen‐Gort
FRFemke Rutters
Femke Rutters
DHDaniëlle Huijts
Daniëlle Huijts
PEPetra Jm Elders
Petra Jm Elders
CTCaroline B. Terwee
Caroline B. Terwee
JHJacqueline G. Hugtenburg
Jacqueline G. Hugtenburg
We aimed to assess the validity of an announced telephone pill count in people with type 2 diabetes or cardiovascular disease by comparing this method to a home‐visit pill count. We also assessed whether a second telephone pill count improved accuracy. People aged ≥35 years using oral type 2 diabetes or cardiovascular disease medication were included. Thirty‐four participants completed a telephone pill count followed by a home‐visit pill count, and a subsample of this population (n = 11) completed a second telephone pill count. Scatterplots were used for a visual representation of the number of pills counted with both methods, intraclass correlation coefficients for agreement, and Bland‐Altman plots for absolute differences and outliers. A total of 203 pill counts were conducted. The study population consisted of 53% men, with a mean age of 69.6 (±9.2) years and an average of 6.1 (±2.8) medication prescriptions per participant. Scatterplots showed that pills counted with both methods were mostly scattered around they = xequation. Agreement between the first telephone pill count and home‐visit pill count was high, with intraclass correlation coefficients of 0.96 (medication count level) and 0.98 (individual level). No learning effects were observed in the subsample (n = 11), the intraclass correlation coefficient for the first telephone pill count was 0.88 versus 0.89 for the second telephone pill count. Bland‐Altman plots indicated high agreement between the two methods. An announced telephone pill count is considered a valid alternative for a home‐visit pill count in people with type 2 diabetes or cardiovascular disease. A single pill count appears sufficient.

30 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MLMarlous Langendoen-Gort
Marlous Langendoen-Gort
DBDebi Bhattacharya
Debi Bhattacharya
HAHiyam Al-Jabr
Hiyam Al-Jabr
MWMaartje de Wit
Maartje de Wit
JHJacqueline G Hugtenburg
Jacqueline G Hugtenburg
FRFemke Rutters
Femke Rutters
Introduction: The aim of this study was to evaluate the implementation and the potential of a pharmacist-led personalised intervention program, aimed at improving medication adherence to oral diabetes and/or hypertension medication in people with type 2 diabetes (T2D), to be normalized in daily clinical practice. Material and methods: A parallel-group randomized controlled trial (RCT) was conducted in 68 participants in 26 community pharmacies from the Netherlands (NL) and the UK. This manuscript reports on a multi-method process analysis that was performed parallel to the six-month follow-up of the RCT. Quantitative data, including data from the data management platform, were analyzed with descriptive statistics. Qualitative data were collected via semi-structured interviews with purposively selected pharmacists (high/low numbers of recruited participants) and participants (high/low satisfaction) and audio-recorded consultations between pharmacists and participants. Semi-structured interviews were analyzed using the Framework approach, the Medical Research Council process evaluation framework of complex interventions and Extended Normalization Process Theory. Audio-recorded consultations were analyzed using the OPTION-12 scale and a self-composed checklist. Results: The fidelity and dose of the intervention program were assessed as high. Consultations were conducted according to the study protocol. Participants’ satisfaction with the intervention modules varied, but overall, participants were satisfied with the clinical medication review, medication schedule, medication dispensing system and referral to their primary care physician. The reach was assessed as low, resulting from selection procedure’ difficulties and only 68 out of the intended 300 participants were recruited. Selection procedure adaptations did not increase the reach. The potential of the intervention program was assessed as high, since pharmacists valued the development of a medication adherence intervention. Contribution was also assessed as high, because of collective action from stakeholders. Finally, capability and capacity were assessed as moderate, due to material resource and workability barriers. Discussion: In its current form the pharmacist-led personalised intervention program cannot be implemented and normalized into daily care. In this process evaluation several barriers including the selection procedure and recruitment of participants have been identified that need to be resolved before the effectiveness of this personalised intervention program can be re-evaluated. Future research should therefore focus on alternative methods for engaging people with T2D with insufficient medication adherence in medication adherence interventions.